Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020GlobeNewsWire • 10/26/20
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/09/20
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual ConferenceGlobeNewsWire • 09/02/20
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/03/20
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business UpdatesGlobeNewsWire • 08/03/20
Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020GlobeNewsWire • 07/27/20
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)GlobeNewsWire • 07/01/20
Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in SessionZacks Investment Research • 06/05/20
How Minerva Neurosciences (NERV) Stock Stands Out in a Strong IndustryZacks Investment Research • 06/02/20
Minerva Neurosciences' stock plummets after schizophrenia treatment disappoints in phase 3 studyMarket Watch • 05/29/20
Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock?Zacks Investment Research • 05/11/20
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/04/20
Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/09/20
Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia GlobeNewsWire • 02/05/20
Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in SchizophreniaGlobeNewsWire • 01/06/20